Bendell, Johanna C <br/><br/>
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  07 2018 
 - 3253-3262 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-17-3421  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers<br/>Combined Modality Therapy<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Neoplasms--diagnosis<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyridines--administration & dosage<br/>Quinolones--administration & dosage<br/>Retreatment<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Treatment Outcome